Device Trial Radar · NCT05397106
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Actual
Start
Jan 24, 2023
Primary completion
Jan 24, 2029
Study completion Jan 24, 2029
Sponsor
- Lead sponsor
- Integra LifeSciences CorporationPublic (IART)
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.
Conditions
- Hydrocephalus
- Hydrocephalus in Children
- NPH (Normal Pressure Hydrocephalus)
- IIH - Idiopathic Intracranial Hypertension
- Brain Tumor
- Post-Traumatic Hydrocephalus
- Hemorrhagic Stroke
Interventions
CODMAN CERTAS Plus Programmable ValveDevice
Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Precise Device Placement: Maintaining Integrity and Functionality at 30 Days Post-DeploymentTime frame: 30 Days
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
University Hospital Leuven
Leuven, Belgium
AZ Delta - Roeselare
Roeselare, Belgium
Klinikum Dortmund Wirbelsäulenchirurgie
Dortmund, Germany
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.